Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha  

Oleh:

Wechowski, Jaroslaw ; Connolly, Mark ; Schneider, Dirk ; McEwan, Philip ; Kennedy, Richard

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 91 no. 04 (Apr. 2009), page 1067-1076.
Topik: Economic evaluation; cost-effectiveness; modeling; gonadotropins; in vitro fertilization; menotropin; recombinant FSH

Ketersediaan

Perpustakaan FK Nomor Panggil: F02.K.2009.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective : To assess the cost-effectiveness of two gonadotropin treatments that are available in the United Kingdom in light of limited public funding and the fundamental role of costs in IVF treatment decisions. Design : An economic evaluation based on two large randomized clinical trials in IVF patients using a simulation model. Setting : Fifty-three fertility clinics in 13 European countries and Israel. Patient(s) : Women indicated for treatment with IVF (N = 986), aged 18–38, participating in double-blind, randomized controlled trials. Intervention(s) : Highly purified menotropin (HP-hMG, Menopur) or recombinant follitropin alpha (rFSH, Gonal-F). Main Outcome Measure(s) : Cost per IVF cycle and cost per live birth for HP-hMG and rFSH alpha. Result(s) : HP-hMG was more effective and less costly versus rFSH for both IVF cost per live birth and for IVF cost per baby (incremental cost-effectiveness ratio was negative). The mean costs per IVF treatment for HP-hMG and rFSH were £2408 (95% confidence interval [CI], £2392, £2421) and £2660 (95% CI £2644, £2678), respectively. The mean cost saving of £253 per cycle using HP-hMG allows one additional cycle to be delivered for every 9.5 cycles. Conclusion(s) : Treatment with HP-hMG was dominant compared with rFSH in the United Kingdom. Gonadotropin costs should be considered alongside live-birth rates to optimize outcomes using scarce health-care resources.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali